Interbody Fusion Device
MINNEAPOLIS, May 6 /PRNewswire-FirstCall/ -- Sulzer Spine-Tech, a
subsidiary of Sulzer Medica Ltd. (NYSE: SM; Swiss Stock Market: SMEN), based
in Minneapolis, Minnesota, has received U.S. Food and Drug Administration
(FDA) approval to begin marketing the BP/Lordotic Interbody Fusion Device for
use in anterior lumbar fusions. The BP/Lordotic device expands Spine-Tech's
offering for the $180 million dollar anterior fusion market.
"The BP/Lordotic cage is the only titanium threaded cage on the market
today that offers surgeons a completely lordotic system. Each instrument in
the BP/Lordotic system helps maintain lordosis from distraction to cage
placement," said Mike McCormick, Executive Vice President and General Manager
of Sulzer Spine-Tech. McCormick went on to say, "the spine is naturally
curved or lordotic and it is important to maintain lordosis to ensure the best
patient outcome. Spine-Tech has been known for its innovation with interbody
devices, the BP/Lordotic System brings that innovation to the instruments as
Lumbar fusions are a common treatment for disabling low back and leg pain
stemming from degenerative disc diseases. The BP/Lordotic fusion system
encompasses an 8 (lordotic angle in all instruments and implants to help
restore lumbar lordosis.
Since its inception in 1991, Sulzer Spine-Tech has focused on designing
and manufacturing comprehensive spine care solutions to improve patients'
quality of life.
Sulzer Medica's subsidiary companies develop, produce, and distribute
medical implants and biological materials for cardiovascular and orthopedic
markets worldwide. The product array includes artificial joints, dental
implants, spinal implants and instrumentation, trauma products, heart valves,
synthetic blood vessels and stents for vascular and non-vascular obstructions.
(Swiss Stock Market symbol: SMEN, New York Stock Exchange symbol: SM).
THE SAFE HARBOR STATEMENTS UNDER THE U.S. PRIVATE SECURITIES LITIGATION
REFORM ACT 1995
This report contains forward-looking statements including, but not limited
to, projections of future performance of materials and products, financial
conditions, results of operations and cash flows, containing risks and
uncertainties. These statements are subject to change based on known risks
detailed from time to time in the Company's Securities and Exchange Commission
filings and other known and unknown risks and various other factors which
could cause the actual results or performance to differ materially from the
statements made herein.
This news release is available on the Internet at:
http://www.sulzermedica.com. The company's annual report 2001 is available on
the Sulzer Medica corporate web site at http://www.sulzermedica.com
"Investors" / "Financial reports".
SOURCE Sulzer Medica Ltd.
/CONTACT: Media - Beatrice Tschanz, +41-1-306-96-46, fax -
+41-1-306-98-37, mobile - +41-79-407-08-78, Andy Bantel, +41-1-306-96-53, fax
- +41-1-306-96-51, mobile - +41-79-231-56-62, or
email@example.com, or Investor Relations - Anja Stubenrauch,
+41-1-306-98-25, fax - +41-1-306-98-31, or
firstname.lastname@example.org, all of Sulzer Medica/
/Web site: http://www.sulzermedica.com/
CO: Sulzer Spine-Tech; Sulzer Medica Ltd.
IN: HEA MTC
-0- May/06/2002 6:48 GMT
Press spacebar to pause and continue. Press esc to stop.